LHRH-agonists in Early Breast Cancer Overview group (2007) Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive ...

The results reported by Sharma et al. suggest that adjuvant LHRH agonist therapy could enhance the response of hormone-sensitive, early-stage breast cancer to standard treatment regimens ...

Here's a rundown of the techniques. Luteinizing hormone-releasing hormone agonists (LHRH agonists.) These are chemicals that stop the production of testosterone in the testicles. Essentially ...

I f prostate cancer has spread to other areas of your body, your doctor may recommend androgen deprivation therapy (ADT), which halts the production of androgen hormones, especially testosterone.

A total of 542 patients had received prior HT, predominantly LHRH agonists (53.7 %); of these, 455 had received prior LHRH analogue therapy (LHRH agonists or GnRH antagonists). Baseline PSA (media ...

Compared with its main comparators, the LHRH agonists, degarelix has the benefit of avoiding an initial ‘testosterone flare’ at the start of treatment. Testosterone flare is thought to increase the ...

The morbidity of contemporary hormone therapies has only recently ... to be equivalent to that associated with orchiectomy, LHRH agonists and NSAAs for patients with metastatic disease.

Remarkably, Relugolix demonstrated a faster return to baseline testosterone levels compared ... was no difference between leuprolide, an LHRH agonist, and relugolix in time to castration resistant ...

The regulator approved the indication based on data showing Kisqali with an aromatase inhibitor improved invasive disease-free survival versus just an aromatase inhibitor.